
1. structure. 2017 oct 3;25(10):1495-1505.e6. doi: 10.1016/j.str.2017.07.015. epub
2017 aug 31.

targeting prolyl-trna synthetase accelerate drug discovery malaria,
leishmaniasis, toxoplasmosis, cryptosporidiosis, coccidiosis.

jain v(1), yogavel m(1), kikuchi h(2), oshima y(2), hariguchi n(3), matsumoto
m(4), goel p(1), touquet b(5), jumani rs(6), tacchini-cottier f(7), harlos k(8), 
huston cd(6), hakimi ma(5), sharma a(9).

author information: 
(1)molecular medicine - structural parasitology group, international centre for
genetic engineering biotechnology (icgeb), aruna asaf ali marg, new delhi
110067, india.
(2)laboratory natural product chemistry, graduate school pharmaceutical
sciences, tohoku university, aoba-yama aoba-ku, sendai 980-8578, japan.
(3)infectious diseases unit, department medical innovations, new drug research
division, otsuka pharmaceutical co., ltd., 463-10, kagasuno, kawauchi-cho,
tokushima 771-0192, japan.
(4)pharmaceutical business division, otsuka pharmaceutical co., ltd., 463-10,
kagasuno, kawauchi-cho, tokushima 771-0192, japan.
(5)institute advanced biosciences (iab), cnrs umr5309, inserm u1209, grenoble
alpes university, 38000 grenoble, france.
(6)department medicine, cell, molecular, biomedical sciences graduate 
program, university vermont college medicine, burlington, vt 05405, usa.
(7)department biochemistry, who-irtc, university lausanne, lausanne 1066,
switzerland.
(8)division structural biology, wellcome trust centre human genetics, 
nuffield department medicine, university oxford, oxford ox3 7bn, uk.
(9)molecular medicine - structural parasitology group, international centre for
genetic engineering biotechnology (icgeb), aruna asaf ali marg, new delhi
110067, india. electronic address: amitpsharma68@gmail.com.

comment in
    structure. 2017 nov 7;25(11):1641-1643.

developing anti-parasitic lead compounds act on key vulnerabilities are
necessary new anti-infectives. malaria, leishmaniasis, toxoplasmosis,
cryptosporidiosis coccidiosis together kill >500,000 humans annually. their
causative parasites plasmodium, leishmania, toxoplasma, cryptosporidium and
eimeria display high conservation many housekeeping genes, suggesting that
these parasites attacked targeting invariant essential proteins. here, 
we describe selective potent inhibition prolyl-trna synthetases (prss)
from parasites using a series of quinazolinone-scaffold compounds.
our prs-drug co-crystal structures reveal remarkable active site plasticity 
accommodates diversely substituted compounds, enzymatic feature be
leveraged refining drug-like properties quinazolinones per parasite
basis. compound termed in-5 exhibited unique double conformation, enhanced
drug-like properties, cleared malaria mice. thus represents new lead 
for optimization. collectively, data offer insights the structure-guided
optimization of quinazolinone-based compounds drug development against
multiple human eukaryotic pathogens.

copyright © 2017 elsevier ltd. rights reserved.

doi: 10.1016/j.str.2017.07.015 
pmid: 28867614  [indexed medline]

